TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).
On October 3, 2025, Quantum BioPharma announced that its Board of Directors has set October 27, 2025, as the record date for distributing contingent value rights (CVRs) to shareholders. These CVRs are linked to potential future litigation settlements from a case against several financial institutions, seeking damages over USD $700 million for alleged stock price manipulation. The CVRs will entitle holders to a portion of any recovered net proceeds, but payments are contingent upon the successful resolution of the litigation. This move aligns potential recoveries with shareholder interests, although there is no guarantee of receiving proceeds.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of its lead compound, Lucid-MS, which aims to address multiple sclerosis. Additionally, Quantum BioPharma has strategic investments and retains a significant stake in Unbuzzd Wellness Inc., a company it spun out for over-the-counter products.
Average Trading Volume: 3,524
Technical Sentiment Signal: Hold
Current Market Cap: C$89.48M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.